Fig. 4
From: Early detection and staging of chronic liver diseases with a protein MRI contrast agent
Detection of portal hypertension during liver cirrhosis in TAA/alcohol- and NASH diet-induced cirrhosis. a R1 map and ΔR1 values of early-stage (Ishak stage 3 of 6), late-stage (Ishak stage 5 of 6), and normal liver (Ishak stage 0 of 6) before and 3 h after injection of ProCA32.collagen1 and Eovist (30 min) in TAA/alcohol model. b R1 changes of liver over different MRI time points after injection of ProCA32.collagen1, ProCA32, and Eovist in TAA/Alcohol model (P < 0.05, paired student’s t test). c R1 map and ΔR1 values of NASH (Ishak 1 of 6), late-stage (Ishak stage 5 of 6), and normal liver (Ishak stage 0 of 6) before and 3 h after injection of ProCA32.collagen1 and Eovist (30 min) in NASH diet model. d R1 changes of liver over different time points after injection of ProCA32.collagen1 and Eovist in NASH diet model (P < 0.05, paired student’s t test). e Representative SEM images of sections from mice with late-stage liver fibrosis in TAA/alcohol model. Quantitation of number and size of fenestrations of liver sinusoids in mice with late-stage liver fibrosis measured by manually counting/measuring number and the diameters of fenestration in the SEM images (scale bar, 500 nm). f Velocity of portal vein blood flow as measured by Doppler ultrasound imaging shows high-portal hypertension detected at 3 h after injection of ProCA32.collagen1 in late-stage liver fibrosis in TAA/alcohol model. g Representative images of IHC stains of CD31 and quantitation of CD31 IHC stains of liver tissue in mice with late-stage liver fibrosis in TAA/alcohol model confirming intrahepatic angiogenesis. scale bar, 100 µm; *P < 0.05, ***P < 0.001, unpaired two-tailed student’s t test; all data are represented as mean ± SD, n = 4 biologically independent animals in each group
